Literature DB >> 11448151

Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness.

R Lever1, C Page.   

Abstract

Glycosaminoglycans (GAGs) are large, polyanionic molecules expressed throughout the body. The GAG heparin, co-released with histamine, is synthesised by and stored exclusively in mast cells, whereas the closely related molecule heparan sulphate is expressed, as part of a proteoglycan, on cell surfaces and throughout tissue matrices. These molecules are increasingly thought to play a role in regulation of the inflammatory response and heparin, for many years, has been considered to hold potential in the treatment of diseases such as asthma. Heparin and related molecules have been found to exert antiinflammatory effects in a wide range of in vitro assays, animal models and, indeed, human patients. Moreover, the results of studies carried out to date indicate that the antiinflammatory activities of heparin are dissociable from its well-established anticoagulant nature, suggesting that the separation of these characteristics could yield novel antiinflammatory drugs which may be useful in the future treatment of diseases such as asthma Copyright Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448151     DOI: 10.1006/pupt.2001.0296

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  9 in total

1.  Mast cells protect mice from Mycoplasma pneumonia.

Authors:  Xiang Xu; Dongji Zhang; Natalya Lyubynska; Paul J Wolters; Nigel P Killeen; Peter Baluk; Donald M McDonald; Samuel Hawgood; George H Caughey
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

2.  Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-11-28       Impact factor: 2.849

3.  Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans.

Authors:  Arrigo F Cicero; Sibel Ertek
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

Review 4.  Extracellular Matrix Component Remodeling in Respiratory Diseases: What Has Been Found in Clinical and Experimental Studies?

Authors:  Juliana T Ito; Juliana D Lourenço; Renato F Righetti; Iolanda F L C Tibério; Carla M Prado; Fernanda D T Q S Lopes
Journal:  Cells       Date:  2019-04-11       Impact factor: 6.600

5.  New drugs targeting Th2 lymphocytes in asthma.

Authors:  Gaetano Caramori; David Groneberg; Kazuhiro Ito; Paolo Casolari; Ian M Adcock; Alberto Papi
Journal:  J Occup Med Toxicol       Date:  2008-02-27       Impact factor: 2.646

6.  Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin.

Authors:  Amir A Gabr; Mathew Reed; Donna R Newman; Jan Pohl; Jody Khosla; Philip L Sannes
Journal:  Respir Res       Date:  2007-05-08

7.  Reduction of Asthmatic Parameters by Sea Hare Hydrolysates in a Mouse Model of Allergic Asthma.

Authors:  Ji Hyeon Ryu; Chengliang Xie; Eun-Jin Kim; Si-Hyang Park; Yeung Joon Choi; Sang Soo Kang; Min-Kyoung Shin; Dawon Kang
Journal:  Nutrients       Date:  2017-07-05       Impact factor: 5.717

Review 8.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

Review 9.  The role of innate immunity in mucopolysaccharide diseases.

Authors:  Helen Parker; Brian W Bigger
Journal:  J Neurochem       Date:  2018-12-13       Impact factor: 5.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.